Bluefish adds new directors to the Board

Bluefish Pharmaceuticals, a Swedish generic pharmaceutical company, strengthens the Board by recruiting Erika Kjellberg Eriksson and Carl Palmstierna , both with extensive experience from the health industry.

New chairperson will be Erika Kjellberg Eriksson, CFO at Q-Med, a Swedish medical technology company, with a history of strong growth through global expansion.

Carl Palmstierna will be a new director of the board. Carl has extensive experience within the health industry through his work at the board of Elekta, a Swedish medical technology company. He also brings a deep knowledge about financing from his many years in the financial industry. Today, he is Managing Partner of ABG Sundal Collier in Sweden.

“Erika’s and Carl’s experiences from working with Swedish companies within the health industry, which have developed into successful global companies, are extremely valuable to Bluefish´s expansion into a European pharmaceutical company” says Karl Karlsson, founder and CEO of Bluefish Pharmaceuticals.

Election of the new board directors will be take place at an Extraordinary General Meeting held on November 22nd, 2007.
For further information contact Karl Karlsson, CEO, tel +46 8 679 50 70

Bluefish Pharmaceuticals AB is a Swedish pharmaceutical company that licenses, develops, manufactures and markets mainly generic pharmaceutical products. Low prices are maintained through efficient production and distribution. Bluefish has a wholly-owned subsidiary in Chennai, India, focusing on product development and production. The company is owned by its founder Karl Karlsson, together with a number of investment funds and private investors.